|
|
|
Registros recuperados: 21 | |
|
| |
|
|
Linden,Rafael; Matte,Ursula. |
Gene therapy attempts the insertion and expression of exogenous genetic material in cells for therapeutic purposes. Conceived in the 1960s, gene therapy reached its first clinical trial at the end of the 1980s and by December 2013 around 600 genuine open clinical trials of gene therapy were registered at NIH Clinical Trials Database. Here, we summarize the current efforts towards the development of gene therapy in Latin America. Our survey shows that the number of scientists involved in the development of gene therapy and DNA vaccines in Latin America is still very low. Higher levels of investment in this technology are necessary to boost the advancement of innovation and intellectual property in this field in a way that would ease both the social and... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Gene therapy; Gene transfer; Gene delivery; Viral vector; South America. |
Ano: 2014 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572014000200015 |
| |
|
| |
|
| |
|
| |
|
|
Buckeridge,Marcos S.; Aidar,Marcos P.M.. |
As carbon dioxide increases on Earth atmosphere, the rise in average temperatures may provoke changes in the environment that could damage civilisation as we know it. As a result, the need to sequester carbon becomes urgent, and one of the options we have is to use the potential of the forests to do it by enhancing assimilation of CO2 through photosynthesis. However, if we consider the use of plants to increase carbon sequestration, a problem that looms is that species often acclimate and actually reduce CO2 assimilation through feedback mechanisms of the sugars that are the product. In the present article, we propose that some biochemical pathways, such as those in control of photosynthesis, carbohydrate metabolism and assimilation, and cellulose and... |
Tipo: Info:eu-repo/semantics/other |
Palavras-chave: Global change; Carbon Sequestration; Photosynthesis; Rain Forest; Sugar Sensing; Cellulose synthesis; Gene therapy. |
Ano: 2002 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1676-06032002000100002 |
| |
|
| |
|
|
Souza,D.S.; Spencer,D.M.; Salles,T.S.I.; Salomão,M.A.; Payen,E.; Beuzard,Y.; Carvalho,H.F.; Costa,F.F.; Saad,S.T.Olalla. |
The effectiveness of the caspase-9-based artificial "death switch" as a safety measure for gene therapy based on the erythropoietin (Epo) hormone was tested in vitro and in vivo using the chemical inducer of dimerization, AP20187. Plasmids encoding the dimeric murine Epo, the tetracycline-controlled transactivator and inducible caspase 9 (ptet-mEpoD, ptet-tTAk and pSH1/Sn-E-Fv’-Fvls-casp9-E, respectively) were used in this study. AP20187 induced apoptosis of iCasp9-modified C2C12 myoblasts. In vivo, two groups of male C57BI/6 mice, 8-12 weeks old, were injected intramuscularly with 5 µg/50 g ptet-mEpoD and 0.5 µg/50 g ptet-tTAk. There were 20 animals in group 1 and 36 animals in group 2. Animals from group 2 were also injected with the 6 µg/50 g iCasp9... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Gene therapy; Erythropoietin; Death switch; Caspase 9; AP20187; Anemia. |
Ano: 2010 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000700005 |
| |
|
|
Poletto,Edina; Pasqualim,Gabriela; Giugliani,Roberto; Matte,Ursula; Baldo,Guilherme. |
Abstract Lysosomal storage diseases (LSDs) are inherited conditions caused by impaired lysosomal function and consequent substrate storage, leading to a range of clinical manifestations, including cardiovascular disease. This may lead to significant symptoms and even cardiac failure, which is an important cause of death among patients. Currently available treatments do not completely correct cardiac involvement in the LSDs. Gene therapy has been tested as a therapeutic alternative with promising results for the heart disease. In this review, we present the results of different approaches of gene therapy for LSDs, mainly in animal models, and its effects in the heart, focusing on protocols with cardiac functional analysis. |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Lysosomal storage disease; Gene therapy; Cardiovascular disease; Animal models; Heart. |
Ano: 2019 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572019000200261 |
| |
|
| |
|
|
EZQUER,FERNANDO; NÚÑEZ,MARCO T; ROJAS,ALEJANDRO; ASENJO,JUAN; ISRAEL,YEDY. |
Levels of body iron should be tightly controlled to prevent the formation of oxygen radicals, lipoperoxidation, genotoxicity, and the production of cytotoxic cytokines, which result in damage to a number of organs. Enterocytes in the intestinal villae are involved in the apical uptake of iron from the intestinal lumen; iron is further exported from the cells into the circulation. The apical divalent metal transporter-1 (DMT1) transports ferrous iron from the lumen into the cells, while the basolateral transporter ferroportin extrudes iron from the enterocytes into the circulation. Patients with hereditary hemochromatosis display an accelerated transepithelial uptake of iron, which leads to body iron accumulation that results in cirrhosis, hepatocellular... |
Tipo: Journal article |
Palavras-chave: Iron; Intestine; Hemochromatosis; Gene therapy; HFE; DMT1; Cirrhosis. |
Ano: 2006 |
URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602006000100014 |
| |
|
|
Poswar,Fabiano de Oliveira; Vairo,Filippo; Burin,Maira; Michelin-Tirelli,Kristiane; Brusius-Facchin,Ana Carolina; Kubaski,Francyne; Souza,Carolina Fischinger Moura de; Baldo,Guilherme; Giugliani,Roberto. |
Abstract Lysosomal diseases (LDs), also known as lysosomal storage diseases (LSDs), are a heterogeneous group of conditions caused by defects in lysosomal function. LDs may result from deficiency of lysosomal hydrolases, membrane-associated transporters or other non-enzymatic proteins. Interest in the LD field is growing each year, as more conditions are, or will soon be treatable. In this article, we review the diagnosis of LDs, from clinical suspicion and screening tests to the identification of enzyme or protein deficiencies and molecular genetic diagnosis. We also cover the treatment approaches that are currently available or in development, including hematopoietic stem cell transplantation, enzyme replacement therapy, small molecules, and gene therapy. |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Lysosomal storage diseases; Neonatal screening; Hematopoietic stem cell transplantation; Enzyme replacement therapy; Gene therapy. |
Ano: 2019 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572019000200165 |
| |
|
| |
|
|
Yamada,André Katayama; Verlengia,Rozangela; Bueno Junior,Carlos Roberto. |
Since its discovery, myostatin (MSTN) has been at the forefront of muscle therapy research because intrinsic mutations or inhibition of this protein, by either pharmacological or genetic means, result in muscle hypertrophy and hyperplasia. In addition to muscle growth, MSTN inhibition potentially disturbs connective tissue, leads to strength modulation, facilitates myoblast transplantation, promotes tissue regeneration, induces adipose tissue thermogenesis and increases muscle oxidative phenotype. It is also known that current advances in gene therapy have an impact on sports because of the illicit use of such methods. However, the adverse effects of these methods, their impact on athletic performance in humans and the means of detecting gene doping are as... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Myostatin; Myostatin/genetic variants; Myostatin/pharmacological inhibitors; Gene doping; Gene therapy; Physical performance; Skeletal muscle. |
Ano: 2012 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502012000300003 |
| |
|
|
Da-Costa,R.C.; Vieira,I.L.; Hunger,A.; Tamura,R.E.; Strauss,B.E.. |
The immune stimulatory and anti-neoplastic functions of type I interferon have long been applied for the treatment of melanoma. However, the systemic application of high levels of this recombinant protein is often met with toxicity. An approach that provides localized, yet transient, production of type I interferon may overcome this limitation. We propose that the use of mesenchymal stem cells (MSCs) as delivery vehicles for the production of interferon-β (IFNβ) may be beneficial when applied together with our cancer gene therapy approach. In our previous studies, we have shown that adenovirus-mediated gene therapy with IFNβ was especially effective in combination with p19Arf gene transfer, resulting in immunogenic cell death. Here we showed that MSCs... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Gene therapy; Immunotherapy; Stem cell therapy; Adenovirus; P53; Interferon-β. |
Ano: 2020 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2020000300601 |
| |
|
|
Lima,Caroline Rocha de Oliveira; Rabelo,Rogério Elias; Vulcani,Valcinir Aloísio Scalla; Cardoso,Lorena Damasio; Sousa,Nicaelle Luan de Moura; Moura,Veridiana Maria Brianezi Dignani de. |
The p53 gene encodes a protein that has molecular weight of 53kD and is also called p53 protein, being constantly studied for its classic concept of "genome guardian". This gene plays a range of essential functions to ensure the cell cycle control, in addition to playing a central role in carcinogenesis. With respect to neoplasias, it prevents the neoplastic transformation through three intricate mechanisms. Depending on the extent of the mutation, different responses may be sent by p53 and those range since the disruption of the cell cycle, the correction of the mutation through the activation of repair proteins or still, the induction of senescence or cell death by apoptosis. This review aims to address the structural and functional aspects of the p53... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Mutations; Neoplasia; Gene therapy; P53. |
Ano: 2012 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782012000500014 |
| |
|
| |
|
| |
|
|
Phillips,M.I.. |
Gene therapy for hypertension is needed for the next generation of antihypertensive drugs. Current drugs, although effective, have poor compliance, are expensive and short-lasting (hours or one day). Gene therapy offers a way to produce long-lasting antihypertensive effects (weeks, months or years). We are currently using two strategies: a) antisense oligodeoxynucleotides (AS-ODN) and b) antisense DNA delivered in viral vectors to inhibit genes associated with vasoconstrictive properties. It is not necessary to know all the genes involved in hypertension, since many years of experience with drugs show which genes need to be controlled. AS-ODN are short, single-stranded DNA that can be injected in naked form or in liposomes. AS-ODN, targeted to angiotensin... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Gene therapy; Hypertension; Antisense; Vectors. |
Ano: 2000 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2000000600013 |
| |
|
|
Dani,S.U.. |
Gene therapy is the treatment of diseases based on the transfer of genetic information. Agents that carry or deliver DNA to target cells are called vectors (Latin vector: carrier, deliverer). Ideally, a vector should accommodate an unlimited amount of inserted DNA, lack the ability of autonomous replication of its own DNA, be easily manufactured, and be available in concentrated form. Secondly, it should have the ability to target specific cell types or to limit its gene expression to specific cell types, and to achieve sustained gene expression in the long term or in a controlled fashion. Finally, it should not be toxic or immunogenic. Such a vector does not exist and none of the DNA delivery systems so far available for in vivo gene transfer is perfect... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Gene therapy; Gene transfer; DNA delivery; Viral vectors; Diposomes; Vector development. |
Ano: 1999 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1999000200001 |
| |
Registros recuperados: 21 | |
|
|
|